0001179110-20-002597.txt : 20200228
0001179110-20-002597.hdr.sgml : 20200228
20200228163919
ACCESSION NUMBER: 0001179110-20-002597
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200226
FILED AS OF DATE: 20200228
DATE AS OF CHANGE: 20200228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hall Ashley
CENTRAL INDEX KEY: 0001801842
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35986
FILM NUMBER: 20671123
MAIL ADDRESS:
STREET 1: C/O ESPERION THERAPEUTICS INC.
STREET 2: 3891 RANCHERO DRIVE SUITE 150
CITY: ANN ARBOR
STATE: MI
ZIP: 48108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Esperion Therapeutics, Inc.
CENTRAL INDEX KEY: 0001434868
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3891 RANCHERO DRIVE, SUITE 150
CITY: ANN ARBOR
STATE: MI
ZIP: 48108
BUSINESS PHONE: 734-887-3903
MAIL ADDRESS:
STREET 1: 3891 RANCHERO DRIVE, SUITE 150
CITY: ANN ARBOR
STATE: MI
ZIP: 48108
FORMER COMPANY:
FORMER CONFORMED NAME: HDL THERAPEUTICS INC
DATE OF NAME CHANGE: 20080513
3
1
edgar.xml
FORM 3 -
X0206
3
2020-02-26
0
0001434868
Esperion Therapeutics, Inc.
ESPR
0001801842
Hall Ashley
C/O ESPERION THERAPEUTICS, INC.
3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR
MI
48108
0
1
0
0
Chief Development Officer
Common Stock
10000
D
Common Stock
5500
D
Stock Option (right to buy)
57.54
2025-08-19
Common Stock
150000
D
Stock Option (right to buy)
21.65
2026-01-04
Common Stock
20000
D
Stock Option (right to buy)
12.88
2027-01-03
Common Stock
27000
D
Stock Option (right to buy)
24.42
2027-02-21
Common Stock
100000
D
Stock Option (right to buy)
66.50
2028-01-02
Common Stock
14000
D
Stock Option (right to buy)
52.38
2028-11-28
Common Stock
30000
D
Stock Option (right to buy)
61.34
2030-01-02
Common Stock
24750
D
These shares were acquired pursuant to a restricted stock unit award under the Amended and Restated 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The restricted stock units vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020.
The options are fully vested as of the date hereof.
The options vest over a four (4) year period in equal quarterly installments, the first of which was on April 3, 2017.
The options vest over a four (4) year period in equal quarterly installments, the first of which was on May 21, 2017.
The options vest over a four (4) year period in equal quarterly installments, the first of which was on April 2, 2018.
The options vest over a four (4) year period in equal quarterly installments, the first of which was on February 28, 2019.
The options vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020.
/s/ Richard B. Bartram, by power of attorney
2020-02-28
EX-24
2
ex24hall.txt
LIMITED POWER OF ATTORNEY
The undersigned hereby constitutes and appoints each of Tim M.
Mayleben and Richard B. Bartram, signing singly, and with full
power of substitution, the undersigned's true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or director of Esperion
Therapeutics, Inc. (the "Company"), from time to time the
following U.S. Securities and Exchange Commission ("SEC") forms:
(i) Form ID, including any attached documents, to effect the
assignment of codes to the undersigned to be used in the
transmission of information to the SEC using the EDGAR System;
(ii) Form 3, Initial Statement of Beneficial Ownership of
Securities, including any attached documents; (iii) Form 4,
Statement of Changes in Beneficial Ownership of Securities,
including any attached documents; (iv) Form 5, Annual Statement
of Beneficial Ownership of Securities in accordance with Section
16(a) of the Securities Exchange Act of 1934, as amended, and the
rules thereunder, including any attached documents; (v) Schedule
13D and (vi) amendments of each thereof, in accordance with the
Securities Exchange Act of 1934, as amended, and the rules
thereunder, including any attached documents;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and
execute any such Form 3, 4 or 5, Schedule 13D or any amendment(s)
thereto, and timely file such form(s) with the SEC and any
securities exchange, national association or similar authority;
and
(3) take any other action of any type whatsoever in
connection with the foregoing which, in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest of,
or legally required by, the undersigned, it being understood that
the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's
discretion.
The undersigned hereby grants to each such attorney-in-fact,
acting singly, full power and authority to do and perform any and
every act and thing whatsoever requisite, necessary or proper to
be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned
might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all
that such attorney-in-fact, or such attorney-in-fact's substitute
or substitutes, shall lawfully do or cause to be done by virtue
of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of
the undersigned, are not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section
16 or Regulation 13D-G of the Securities Exchange Act of 1934, as
amended. The undersigned hereby agrees to indemnify the attorney
in fact and the Company from and against any demand, damage,
loss, cost or expense arising from any false or misleading
information provided by the undersigned to the attorney-in fact.
This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file such forms
with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing
attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of 24 January, 2020.
/s/ Ashley Hall
________________
Ashley Hall